样式: 排序: IF: - GO 导出 标记为已读
-
Sofosbuvir (+) daclatasvir (+) ribavirin in Egyptian patients with hepatitis C virus: Therapeutic outcomes and the prognostic role of natural killer cells Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2024-03-01 Ahmed B. Zaid, Shimaa K. Almady, Samah M. Awad, Mona G. Elabd, Sara A. Saied, AbdulRahman A Saied, Alshimaa M Elmalawany
One of the prominent causes of chronic liver disease worldwide is the hepatitis C virus (HCV). HCV believed that innate immunity contributes to a sustained virological response (SVR) to the treatment of Sofosbuvir (SOF) (+) Daclatasvir (DCV) (+) Ribavirin (RBV). This study aimed to evaluate the impact of SOF (+) DCV (+) RBV therapy and persistent HCV infection on the subset of natural killer cells
-
In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamide Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2024-03-01 Emine Begum Gencer, Hasan Yalim Akin, Selami Kocak Toprak, Eylul Turasan, Mahsa Yousefzadeh, Pinar Yurdakul-Mesutoglu, Murat Cagan, Mehmet Murat Seval, Doruk Cevdi Katlan, Klara Dalva, Mehmet Sinan Beksac, Meral Beksac
High self-renewal capacity and most permissive nature of umbilical cord blood (CB) results with successful transplant outcomes but low hematopoietic stem and progenitor cell (HSPC) counts limits wider use. In order to overcome this problem expansion with small molecules such as Valproic acid (VPA) or Nicotinamide (NAM) have been shown to be effective. To the best of our knowledge, the combinatory effects
-
Application of chimeric antigen receptor therapy beyond oncology: A bibliometric and visualized analysis Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2024-02-06 Linxin Yang, Jinshen He, Jiahao Liu, Tianjian Xie, Qi Tang
Chimeric antigen receptor therapy beyond oncology has gained increasing attention. While a substantial number of publications have emerged in recent years, there has been a paucity of conducted bibliometric studies. Our objective is to systematically summarize and visually analyze the literature in the field of chimeric antigen receptors therapy beyond oncology and explore hotspots in this field. Web
-
Role of next-generation sequencing in acquired amegakaryocytic thrombocytopenic purpura Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2024-01-26 Lorenzo Lazzari, Lucia Bongiovanni, Paola Ronchi, Gregorio Maria Bergonzi, Camilla Gariazzo, Elisa Diral, Fabio Ciceri, Andrea D'Alessio, Maurilio Ponzoni
Abstract not available
-
Luspatercept for the treatment of congenital sideroblastic anemia: two case reports Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2024-01-12 Yuanyuan Shao, Li He, Shaoxue Ding, Rong Fu
Congenital sideroblastic anemia (CSA) is a group of disorders caused by different genetic mutations that result in low iron utilization and ineffective erythropoiesis. Current treatments are limited, and some patients do not respond to vitamin B6 therapy. Luspatercept is a novel erythropoietic maturation agent approved for adult β-thalassemia and Myelodysplastic syndromes with ring sideroblasts (MDS-RS)
-
Cytogenetics in the management of hematological malignancies: An overview of alternative technologies for cytogenetic characterization Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2024-01-12 Valentin Lestringant, Hélène Guermouche-Flament, Mélanie Jimenez-Pocquet, Jean-Baptiste Gaillard, Dominique Penther
Genomic characterization is an essential part of the clinical management of hematological malignancies for diagnostic, prognostic and therapeutic purposes. Although CBA and FISH are still the gold standard in hematology for the detection of CNA and SV, some alternative technologies are intended to complement their deficiencies or even replace them in the more or less near future. In this article, we
-
The clinical applications of immunosequencing Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2024-01-12 B. Bardwell, J. Bay, Z. Colburn
Technological advances in high-throughput sequencing have opened the door for the interrogation of adaptive immune responses at unprecedented scale. It is now possible to determine the sequences of antibodies or T-cell receptors produced by individual B and T cells in a sample. This capability, termed immunosequencing, has transformed the study of both infectious and non-infectious diseases by allowing
-
Autologous intraarterial pancreatic bone-marrow mononuclear cells infusion in T2D patients: Changes on beta-cells function, insulin resistance, and inflammatory marker Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-12-29 Farid Kurniawan, Imam Subekti, Em Yunir, Dante Saksono Harbuwono, Dyah Purnamasari, Tri Juli Edi Tarigan, Wismandari Wisnu, Dicky Levenus Tahapary, Syahidatul Wafa, Cindy Astrella, Eunike Vania Christabel, Anna Mira Lubis, Ika Prasetya Wijaya, Birry Karim, Mohamad Syahrir Azizi, Indrati Suroyo, Sahat Matondang, Krishna Pandu Wicaksono, Dewi Wulandari, Iqbal Fasha, Pradana Soewondo
Background Type 2 diabetes (T2D) is a progressive disease. Many drugs currently being used for the management of T2D have minimal effect on pancreatic beta cells regeneration. Cell-based therapies might provide potential benefits in this aspect. Methods A pilot study in five T2D patients with 12 months follow-up was performed to evaluate the effect of autologous bone marrow mononuclear stem cells (BM-MNCs)
-
Overlapping features of hepatic complications after hematopoietic cell transplantation in a rare T-cell lymphoma: A clinical challenge Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-12-20 Andrea Nunzi, Giulia Ciangola, Ilaria Cerroni, Valeria Mezzanotte, Gentiana Elena Trotta, Federico Meconi, Annagiulia Zizzari, Vito Mario Rapisarda, Luca Savino, Arianna Brega, Renato Argirò, Gottardo De Angelis, Benedetta Mariotti, Fabrizio Bonanni, Elisa Meddi, Carmelo Gurnari, Antoine Bruno, Ilaria Mangione, Adriano Venditti, Raffaella Cerretti
We present the case of a young adult, who developed several hepatic post-HCT complications, which made differential diagnosis extremely difficult.
-
Cytogenetics in the management of B-cell acute lymphoblastic leukemia: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH) Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-11-24 Giulia Tueur, Julie Quessada, Jolien De Bie, Wendy Cuccuini, Saloua Toujani, Christine Lefebvre, Isabelle Luquet, Lucienne Michaux, Marina Lafage-Pochitaloff
Cytogenetic analysis is mandatory at initial assessment of B-cell acute lymphoblastic leukemia (B-ALL) due to its diagnostic and prognostic value. Results from chromosome banding analysis and complementary FISH are taken into account in therapeutic protocols and further completed by other techniques (RT-PCR, SNP-array, MLPA, NGS, OGM). Indeed, new genomic entities have been identified by NGS, mostly
-
Catechol-O-methyltransferase gene (COMT) is associated with neurocognitive functioning in patients with sickle cell disease Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-11-21 Andrew M. Heitzer, Sara R. Rashkin, Ana Trpchevska, Jennifer N. Longoria, Evadnie Rampersaud, Yunusa Olufadi, Winfred C. Wang, Darcy Raches, Brian Potter, Martin H Steinberg, Allison A. King, Guolian Kang, Clifford M. Takemoto, Jane S. Hankins
Purpose Neurocognitive impairment is a common and debilitating complication of sickle cell disease (SCD) resulting from a combination of biological and environmental factors. The catechol-O-methyltransferase (COMT) gene modulates levels of dopamine availability in the prefrontal cortex. COMT has repeatedly been implicated in the perception of pain stimuli and frequency of pain crises in patients with
-
Cytogenetics in the management of T-cell acute lymphoblastic leukemia (T-ALL): Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH) Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-11-19 Jolien De Bie, Julie Quessada, Giulia Tueur, Christine Lefebvre, Isabelle Luquet, Saloua Toujani, Wendy Cuccuini, Marina Lafage-Pochitaloff, Lucienne Michaux
Molecular analysis is the hallmark of T-cell acute lymphoblastic leukemia (T-ALL) categorization. Several T-ALL sub-groups are well recognized based on the aberrant expression of specific transcription factors. This recently resulted in the implementation of eight provisional T-ALL entities into the novel 2022 International Consensus Classification, albeit not into the updated World Health Organization
-
Adjusting diffusing capacity for anemia in patients undergoing allogeneic HCT: a comparison of two methodologies Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-11-19 Hemang Yadav, Mehrdad Hefazi Torghabeh, Sumedh S Hoskote, Kelly M Pennington, Kaiser G Lim, Paul D Scanlon, Alexander S Niven, William J Hogan
Background Diffusing capacity (DLCO) measurements are affected by hemoglobin. Two adjustment equations are used: Cotes (recommended by ATS/ERS) and Dinakara (used in the hematopoietic stem cell transplantation comorbidity index [HCT-CI]). It is unknown how these methods compare, and which is better from a prognostication standpoint. Study design This is a retrospective cohort of 1273 adult patients
-
Performances of the H-score and the HLH-2004 score in the positive diagnosis of secondary hemophagocytic lymphohistiocytosis Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-11-08 Abida Fatma, Ben Salah Raida, Chaari Mourad, Dammak Ikram, Bahloul Zouheir, Elleuch Henda
Hemophagocytic lymphocytosis (HLH) is a rare clinical and biological entity that can be life-threatening. Early diagnosis can improve the overall prognosis of HLH. Objectives The aims of this study are to evaluate the performances of HLH-2004-score and H-score in identifying patients with secondary HLH and to determine an optimal H-score cut-off for our population. Methods A retrospective study that
-
Investigating the multifaceted cooperation of autophagy, PI3K/AKT signaling pathways, and INPP4B gene in de novo acute myeloid leukemia patients Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-11-01 Mahnaz Gorji, Mehdi Allahbakhshian Farsani, Maryam Kargar, Javad Garavand, Mohammad Hossein Mohammadi
Background Acute myeloid leukemia (AML) has been the most prevalent form of acute leukemia among adults, and it has been associated with poor survival rates over the last four decades. Understanding the processes involved in leukemogenesis, particularly autophagy and signaling pathways, can provide critical insights into their roles in disease development, risk assessment, and potential therapeutic
-
Cytogenetics in the management of mature T-cell and NK-cell neoplasms: Guidelines from the groupe francophone de cytogénétique hématologique (GFCH) Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-10-31 Jean-Baptiste Gaillard, Elise Chapiro, Agnès Daudignon, Nathalie Nadal, Dominique Penther, Jasmine Chauzeix, Florence Nguyen-Khac, Lauren Veronese, Christine Lefebvre
Mature T-cell and natural killer (NK)-cell neoplasms (MTNKNs) are a highly heterogeneous group of lymphomas that represent 10–15 % of lymphoid neoplasms and have usually an aggressive behavior. Diagnosis can be challenging due to their overlapping clinical, histological and immunophenotypic features. Genetic data are not a routine component of the diagnostic algorithm for most MTNKNs. Indeed, unlike
-
Cytogenetics in the management of clonal chromosomal abnormalities of undetermined significance and persistent polyclonal B-cell lymphocytosis: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH) Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-10-26 N. Nadal, N. Auger, A. Bidet, F. Nguyen-Khac
Acquired clonal chromosomal abnormalities (CAs) are usually considered to be disease-related. However, when a CA of this type is the only abnormality present (and especially in small clones), the clinical significance is unclear. Here, we review the literature on recurrent CAs whose significance is regularly subject to debate. Our objective was to help with their interpretation and develop guidelines
-
Cytogenetics in the management of multiple Myeloma: The guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH) Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-10-24 Agnès Daudignon, Wendy Cuccuini, Claire Bracquemart, Catherine Godon, Benoit Quilichini, Dominique Penther
Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells (PCs) in the bone marrow. Despite considerable advances in the treatment, MM is considered an incurable chronic disease with a very heterogeneous prognosis, mostly depending on genomic alterations whose complexity evolves over time. The cytogenetic analysis of MM is performed on CD138+ sorted PCs, in order to detect
-
Cytogenetics in the management of mature B-cell non-Hodgkin lymphomas: Guidelines from the Groupe Francophone de Cytogénétique Hematologique (GFCH) Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-10-23 C. Lefebvre, L. Veronese, N. Nadal, J.-B. Gaillard, D. Penther, A. Daudignon, J. Chauzeix, F. Nguyen-Khac, E. Chapiro
Non-Hodgkin lymphomas (NHL) consist of a wide range of clinically, phenotypically and genetically distinct neoplasms. The accurate diagnosis of mature B-cell non-Hodgkin lymphoma relies on a multidisciplinary approach that integrates morphological, phenotypical and genetic characteristics together with clinical features. Cytogenetic analyses remain an essential part of the diagnostic workup for mature
-
Cytogenetic abnormalities in hematologic neoplasms with germline predisposition Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-10-21 Nathalie Gachard, Marina Lafage-Pochitaloff, Julie Quessada, Nathalie Auger, Marie-Agnès Collonge-Rame
The number of predisposing genes is continuously growing with the widespread availability of DNA sequencing, increasing the prevalence of hematologic malignancies with germline predisposition. Cytogenetic analyses provide an effective approach for the recognition of these malignancies with germline predisposition, which is critical for proper diagnosis, optimal treatment and genetic counseling. Based
-
Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytogénétique Hématologique (GFCH) Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-10-20 Matthieu Decamp, Emilie Klein, Catherine Godon, Valentin Lestringant, Pauline Roynard, Olivier Theisen, Mélanie Jimenez-Pocquet, Catherine Roche-Lestienne, Audrey Bidet, Lauren Veronese
Myeloproliferative neoplasms, mastocytosis, myeloid/lymphoid neoplasms with hypereosinophilia and tyrosine kinase gene fusions, and myelodysplastic/myeloproliferative neoplasms are clonal hematopoietic cancers that, with the exception of certain entities, have an indolent course. In addition to their increasingly important role in the diagnosis of these entities, as shown by the recent classification
-
Cytogenetics in the management of hematological malignancies: Guidelines from the Groupe Francophone de Cytogénétique Hématologique Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-10-19 Florence Nguyen-Khac, Audrey Bidet, Elise Chapiro, Christine Lefebvre, Lucienne Michaux, Marie-Bérengère Troadec
Abstract not available
-
Cytogenetics in the management of bone marrow failure syndromes: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH) Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-10-18 Wendy Cuccuini, Marie-Agnes Collonge-Rame, Nathalie Auger, Nathalie Douet-Guilbert, Lucie Coster, Marina Lafage-Pochitaloff
Bone marrow failure syndromes are rare disorders characterized by bone marrow hypocellularity and resultant peripheral cytopenias. The most frequent form is acquired, so-called aplastic anemia or idiopathic aplastic anemia, an auto-immune disorder frequently associated with paroxysmal nocturnal hemoglobinuria, whereas inherited bone marrow failure syndromes are related to pathogenic germline variants
-
Oral minocycline as systemic therapy for uncomplicated venous access device-related bloodstream infection with coagulase-negative staphylococci after allogeneic hematopoietic cell transplantation Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-10-16 Firas Bayoudh, Jean-Baptiste Giot, Julie Descy, Corentin Fontaine, Marie-Pierre Hayette, Frédéric Baron, Evelyne Willems, Yves Beguin, Frédéric Frippiat, Sophie Servais
Background Venous access device-related bloodstream infection (VAD-BSI) with coagulase-negative staphylococci (CoNS) is a common complication after allogeneic hematopoietic cell transplantation (alloHCT). Standard systemic antimicrobial therapy for uncomplicated VAD-BSI with methicillin-resistant CoNS consists of intravenous (IV) vancomycin (vanco). This requires hospitalization, needs new competent
-
Cytogenetics in the management of acute myeloid leukemia and histiocytic/dendritic cell neoplasms: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH) Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-10-16 Audrey Bidet, Julie Quessada, Wendy Cuccuini, Matthieu Decamp, Marina Lafage-Pochitaloff, Isabelle Luquet, Christine Lefebvre, Giulia Tueur
Genetic data are becoming increasingly essential in the management of hematological neoplasms as shown by two classifications published in 2022: the 5th edition of the World Health Organization Classification of Hematolymphoid Tumours and the International Consensus Classification of Myeloid Neoplasms and Acute Leukemias. Genetic data are particularly important for acute myeloid leukemias (AMLs) because
-
-
-
Cardiovascular Risk in a Contemporary Cohort of Patients with Myeloproliferative Neoplasms’ Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-10-13 D. Mehta, J.A. Henry, S. Ahmed, S. Alimam, A.K. Ghosh, S. Tyebally, J.M. Walker, R. Patel, R. Amerikanou, J. O'Nions, A.J. Wilson, J. Lambert, D.P. McLornan, M. Sekhar, D. Chen
Background Myeloproliferative neoplasms (MPNs) are a group of disorders of clonal haemopoiesis associated with an inherent risk of arterial and venous thrombotic complications. The prevalence of thrombotic complications and the impact of cardiovascular risk factors (CVRFs) in contemporary patient cohorts within the current era of MPN treatments have not been completely defined. Objectives We aim to
-
Pyroptosis in sepsis induced organ dysfunction Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-10-06 Ruoyu Song, Shijun He, Yongbin Wu, Sipin Tan
As an uncontrolled inflammatory response to infection, sepsis and sepsis induced organ dysfunction are great threats to the lives of septic patients. Unfortunately, the pathogenesis of sepsis is complex and multifactorial, which still needs to be elucidated. Pyroptosis is a newly discovered atypical form of inflammatory programmed cell death, which depends on the Caspase-1 dependent classical pathway
-
Association of Normal and Mutated APOL1 G2 Rs60910145 allele with SCD, Body Mass Index, and Renal Function Biomarkers and Indices Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-09-29 Abazar Mahmoud Ismail, Bakri Mohammed Nour, Adam Dawoud Abakar, Babiker Saad Almugadam, Hisham N. Altayb, Rania TagEsir Ahmed, Mubarak Elsaeed Mustafa Elkarsany
Purpose of the study : The current study aimed to detect the frequency of normal and mutated APOL1 alleles in sickle cell disease (SCD) patients and test their relation with Microalbuminuria, Creatinine, Urea, Glomerular Filtration Rate (GFR), and Body Mass Index (BMI). Patients and Methods : The study included 156 SCD subjects. Serum Creatinine (mg/dl) and Urea (mg/dl) as well as Microalbuminuria
-
Exploration of the mechanism of reinfusion of fresh autologous blood in type 2 diabetic body to induce macrophage polarization and inhibit erythrocyte damage Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-09-29 She-jun Hu, Jia-ming Xu, Man-di Wu, Ke Yue, Ying-hui Cui, Yu Bai, Lai-wei You, Jian-Rong Guo
Background Type 2 diabetes (T2D) triggers an inflammatory response that can damage red blood cells. M2 macrophages have inhibitory effects on inflammation and play an important role in tissue damage repair and fibrosis. Autologous blood transfusion has the potential to inhibit red blood cell damage by mediating macrophage polarization. Methods Swiss mice were used to establish a suitable type 2 diabetes
-
Biochemical Pancreatic β-Cell Lineage Reprogramming: Various Cell Fate Shifts Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-09-21 Yuqin Wang, Zhuoqing Liu, Shengren Li, Xuejuan Su, Keng Po Lai, Rong Li
The incidence of pancreatic diseases has been continuously rising in recent years. Thus, research on pancreatic regeneration is becoming more popular. Chronic hyperglycemia is detrimental to pancreatic β-cells, leading to impairment of insulin secretion which is the main hallmark of pancreatic diseases. Obtaining plenty of functional pancreatic β-cells is the most crucial aspect when studying pancreatic
-
Cytogenetics in the management of chronic lymphocytic leukemia: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH) Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-09-17 Florence Nguyen-Khac, Zsofia Balogh, Jasmine Chauzeix, Lauren Veronese, Elise Chapiro
Chromosomal abnormalities are frequent in chronic lymphocytic leukemia (CLL), and most have prognostic value. In addition to the four well-known abnormalities (13q, 11q and 17p deletions, and trisomy 12), other recurrent aberrations have been linked to the disease outcome and/or drug resistance. Moreover, the complex karyotype has recently emerged as a prognostic marker for patients undergoing immunochemotherapy
-
Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH) Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-09-17 Nathalie Auger, Nathalie Douet-Guilbert, Julie Quessada, Olivier Theisen, Marina Lafage-Pochitaloff, Marie-Bérengère Troadec
Myelodysplastic neoplasms (MDS) are clonal hematopoietic neoplasms. Chromosomal abnormalities (CAs) are detected in 40–45% of de novo MDS and up to 80% of post-cytotoxic therapy MDS (MDS-pCT). Lately, several changes appeared in World Health Organization (WHO) classification and International Consensus Classification (ICC). The novel ‘biallelic TP53 inactivation’ (also called ‘multi-hit TP53’) MDS
-
Exploring clues pointing toward the existence of a brain-gut microbiota-hair follicle axis Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-09-10 Yang Feng
Proposing the concept of a brain-gut-skin axis has led some researchers to recognize the relationship among brain activity, gut microbiota, and the skin. Hair follicles are significant skin accessory organs, a previously unnoticed target tissue for classical neurohormones, neurotrophins, and neuropeptides. Some studies have shown a relationship between the central nervous system and hair follicles
-
Role of Interim PET/CT as Predictor of Outcome in Newly Diagnosed Diffuse Large B-Cell Lymphoma in the Chemo-immunotherapy Era Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-07-27 Moussab Damlaj, Waed Jaber, Afnan Al Najjar, Sumayyah Altamimi, Tarfa Al Onazi, Mohammed Alzayed, Ahmad Damlaj, Rehab Yassin, Bader Alahmari, Ayman Alhejazi, Giamal Gmati, Khadega Abuelgasim, Hind Salama, Ahmed Alaskar, Mohsen Al Zahrani
Abstract not available
-
Bone marrow alterations in COVID-19 infection: The root of hematological problems Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-07-25 Fatemeh Zeylabi, Najmeh Nameh Goshay Fard, Abazar Parsi, Seyed Mohammad Sadegh Pezeshki
Introduction The 2019 coronavirus disease (COVID-19) is a respiratory infection caused by the SARS-CoV-2 virus with a significant impact on the hematopoietic system and homeostasis. The effect of the virus on blood cells indicates the involvement of the bone marrow (BM) as the place of production and maturation of these cells by the virus and it reminds the necessity of investigating the effect of
-
Coexistence of three hematological malignancies in association with a first time documented mutation: “One train can hide another”°, and even more! Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-07-13 Tamim Alsuliman, Souhila Ikhlef, Nicolas Stocker, Fazia Kaoui, Laure Ricard, Malek Aoudjhane, Mohamad Mohty, Zora Marjanovic
Coexisting malignancies is not only an uncommon event but, it can also represent a medical challenge. Its complexity relies on the difficulty of management and the need for personalized and prioritized therapeutic approaches, on the one hand, and in the potential misdiagnosis of recurrence or even a de novo disease, on the other. Here, we present a case of a 69-year-old patient, who was initially diagnosed
-
Primary prevention of cancer-associated venous thrombosis: Rationale and challenges in clinical practice Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-07-13
-
Advances in adoptive T-cell therapy for metastatic melanoma Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-07-07 Aparimita Das, Aruni Ghose, Kevin Naicker, Elisabet Sanchez, Cyrus Chargari, Elie Rassy, Stergios Boussios
Adoptive T cell therapy (ACT) is a fast developing, niche area of immunotherapy (IO), which is revolutionising the therapeutic landscape of solid tumour oncology, especially metastatic melanoma (MM). Identifying tumour antigens (TAs) as potential targets, the ACT response is mediated by either Tumour Infiltrating Lymphocytes (TILs) or genetically modified T cells with specific receptors – T cell receptors
-
Impact of tixagevimab/cilgavimab prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplants and CAR T-cell therapy: A single center experience Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-06-28 Elisabetta Xue, Gianluca Scorpio, Annalisa Ruggeri, Daniela Clerici, Francesca Farina, Edoardo Campodonico, Andrea Acerbis, Paolo Fiore, Alessandro Bruno, Matteo G Carrabba, Jacopo Peccatori, Raffaella Greco, Maria Teresa Lupo Stanghellini, Fabio Ciceri, Consuelo Corti
Abstract not available
-
Establishment and characterization of a novel breast implant-associated anaplastic large cell lymphoma cell line and PDX model (BIA-XR1) with a unique KRAS mutation Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-06-20 Ioanna Xagoraris, Konstantina Stathopoulou, Roberta D' Aulerio, Minghui He, Anett Ketscher, Kenbugul Jatta, Felix Haglund de Flon, Gisela Barbany, Richard Rosenquist, Lisa S. Westerberg, George Z. Rassidakis
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell lymphoma type with distinct clinical, molecular and genetic features. Establishment of BIA-ALCL cell lines and patient-derived xenograft (PDX) models are essential experimental tools to investigate the molecular pathogenesis of the disease. We characterized a novel BIA-ALCL cell line and PDX model, named BIA-XR1
-
Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-06-13 P Sriskandarajah, D P McLornan, C Oni, AJ Wilson, C Woodley, M Ciesielska, K Raj, R Dillon, M Ethell, J Chacko, K Orchard, DH Radia
Advanced systemic mastocytosis (AdvSM) is a rare, life-limiting mast cell (MC) neoplasm, with approximately 70% patients having an associated haematological neoplasm (AHN). Avapritinib, a selective tyrosine kinase inhibitor targeting KIT D816V, has shown potent activity translating clinically into durable responses in the phase 1 EXPLORER (NCT02561988) and phase 2 PATHFINDER (NCT03580655) studies.
-
Splenic irradiation prior to allogeneic transplant conditioning in myelofibrosis: A pilot experience Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-06-09 Edoardo Campodonico, Elisabetta Xue, Simona Piemontese, Anna Chiara, Alessandro Bruno, Gianluca Scorpio, Rosamaria Nitti, Daniele Sannipoli, Giorgio Orofino, Paolo Fiore, Maria Chiara Quattrocchi, Elisa Diral, Daniela Clerici, Francesca Farina, Consuelo Corti, Francesca Lunghi, Maria Teresa Lupo-Stanghellini, Nadia Di Muzio, Fabio Ciceri, Raffaella Greco, Jacopo Peccatori
Introduction In the era of JAK inhibitors, allogeneic stem cell transplantation (HSCT) remains the only curative treatment for patients with Myelofibrosis (MF). Splenic irradiation (SI) may be used to reduce spleen size and related symptoms. Methods We conducted a retrospective analysis on 14 patients with MF who underwent HSCT with SI from any donor source at our center between June 2016 and March
-
Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-04-23 Talha Badar, Hassan Alkhateeb, Mahmoud Aljurf, Mohamed A. Kharfan-Dabaja
Before the advent of tyrosine kinase inhibitors (TKI) the outcome of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) was dismal. The TKI combination with induction regimens has greatly improved the long-term outcome of Ph+ ALL, specifically ponatinib a most potent TKI in combination with HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone)
-
Scaling up human mesenchymal stem cell manufacturing using bioreactors for clinical uses Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-04-28 Marina Gazdic Jankovic, Miodrag Stojkovic, Sanja Bojic, Nemanja Jovicic, Marina Miletic Kovacevic, Zeljko Ivosevic, Aleksandar Juskovic, Vojin Kovacevic, Biljana Ljujic
Human mesenchymal stem cells (hMSCs) are multipotent cells and an attractive therapeutic agent in regenerative medicine and intensive clinical research. Despite the great potential, the limitation that needs to be overcome is the necessity of ex vivo expansion because of insufficient number of hMSCs presented within adult organs and the high doses required for a transplantation. As a result, numerous
-
Plasma cell-directed therapy and anti-HLA antibody production: A successful combination? Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-04-14 Martina Soldarini, Annamaria Cafro, Paola Bertazzoni, Marialuisa Pioltelli, Giorgia Cornacchini, Giuliana Lando, Elisabetta Sommaruga, Antonio Milano, Roberto Cairoli, Silvano Rossini, Roberto Crocchiolo
Abstract not available
-
Are we there yet? cellular therapies for cutaneous T cell lymphoma Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-04-06 Pinar Ataca Atilla, Erden Atilla
Cutaneous T cell lymphomas (CTCLs) are a heterogenous group of skin-involved T-cell non-Hodgkin lymphoma which Mycosis Fungoides and Sezary Syndrome are the most common variants. Despite considerable progress in distinguishing the pathophysiology, the treatment options are still limited for advanced-stage disease. Recent approval of novel agents such as vorinostat, brentuximab vedotin and mogamulizumab
-
Regulatory factors involved in Th17/Treg cell balance of immune thrombocytopenia Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-04-05 Masoud Kargar, Mehdi Torabizadeh, Daryush Purrahman, Zeinab Deris Zayeri, Najmaldin Saki
Immune thrombocytopenia is a common heterogeneous autoimmune disease that is characterized by decreasing peripheral blood platelet counts and increasing risk of bleeding. Studies have shown that an imbalance between T helper 17 (Th17) and Regulatory T (Treg) cells differentiated from CD4+T-cells is a key factor influencing the development and pathogenesis of immune thrombocytopenia. Th17 cells promote
-
Failure to bispecific-antibody therapy is associated with a short survival in highly pre-treated patients with aggressive B-Cell Lymphomas Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-03-26 Kohar Kevork, Melanie Gouin, Valentin Letailleur, Patrice Chevallier, Cyrille Touzeau, Thomas Gastinne, Bénédicte Piron, Benoît Tessoulin
Abstract not available
-
Timing of cyclosporine administration for GvHD prophylaxis in haploidentical stem cell transplantation setting: Single center experience Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-03-21 Jean El Cheikh, Layal Sharrouf, Mahdi Hamade, Khodr Terro, Ghassan Bidaoui, Maya Charafeddine, Fatima Ismail, Ammar Zahreddine, Nour Moukalled, Imane Abou Dalle, Ali Bazarbachi
Abstract not available
-
New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-02-26 Giorgia Battipaglia, Annamaria Vincenzi, Giulia Falconi, Alessia Fiore, Francesco D'Agostino, Raffaella Iannotta, Francesco Grimaldi, Carmelo Gurnari, Elisa Galossi, Elena Crisà, Francesca Bonello, Giulia Scalia, Barbara Izzo, Maria Teresa Voso, Fabrizio Pane
Abstract not available
-
CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-02-04 Clémentine Nicod, Mathieu Neto da Rocha, Walid Warda, Xavier Roussel, Rafik Haderbache, Evan Seffar, Rim Trad, Lucie Bouquet, Mathieu Goncalves, Léa Bosdure, Marie-Charlotte Laude, Mélanie Guiot, Christophe Ferrand, Marina Deschamps
Purpose of the study The use of chimeric antigen receptor (CAR)-T cells has demonstrated excellent results in B-lymphoid malignancies. The Advanced Therapy Medicinal Products (ATMP) status and good manufacturing practice (GMP) of CAR-T cells require particular conditions of production performed in a pharmaceutical establishment. Our team developed a new medical drug candidate for acute myeloid leukemia
-
Current research in translational medicine - biostatistical recommendations for authors Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-01-28 Michal Ordak
Abstract not available
-
Antibodies to calnexin and mutated calreticulin are common in human sera Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-01-28 C Kyllesbech, N Trier, F Mughal, P Hansen, M Holmström, D el Fassi, H Hasselbalch, V Skov, L Kjær, M Andersen, E Ciplys, R Slibinskas, J Frederiksen, P Højrup, G Houen
Purpose of the study Calreticulin is an endoplasmic reticulum chaperone protein, which is involved in protein folding and in peptide loading of major histocompatibility complex class I molecules together with its homolog calnexin. Mutated calreticulin is associated with a group of hemopoietic disorders, especially myeloproliferative neoplasms. Currently only the cellular immune response to mutated
-
mRNA-lncRNA gene expression signature for predicting pediatric AML relapse Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-01-25 E.D. Kulaeva, E.V. Mashkina
Children with acute myeloid leukemia (AML) face a relapse of the disease in 30% of all cases. AML relapse is difficult to predict, and existing risk scales are often ineffective. Using data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET-AML) project, we defined an expression signature based on matrix RNAs (mRNAs) and long non-coding RNAs (lncRNAs) that could predict
-
Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-01-12 Ying Shen, Jie Liu, Baiyan Wang, Yilin Zhang, Yan Xu, Xiaman Wang, Yachun Jia, Xin Meng, Xugeng Wang, Xiaohu Fan, Aili He, Wanhong Zhao
Purpose Chimeric antigen receptor T-cell (CAR-T) therapy has been proven very effective in treating hematologic malignancies. Ciltacabtagene autoleucel (cilta-cel), a second-generation CAR-T cell with double B cell maturation antigen (BCMA) targeting binding domains, showed an 88% overall response rate (ORR) in patients with relapsed/refractory multiple myeloma (MM), which were carried out in our institute
-
Current status of producing autologous hematopoietic stem cells Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2023-01-05 Zhonglin Li, Ling Yang
-
In vitro blood brain barrier models: Molecular aspects and therapeutic strategies in glioma management Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2022-12-20 Vinitha Rani, Ashwini Prabhu
-
Causal analysis of plasma IL-8 on carotid intima media thickness, a measure of subclinical atherosclerosis Curr. Res. Transl. Med. (IF 4.1) Pub Date : 2022-12-06 Ilais Moreno Velásquez, Anders Malarstig, Damiano Baldassarre, Yan Borne, Ulf de Faire, Gunnar Engström, Per Eriksson, Philippe Giral, Steve E. Humphries, Sudhir Kurl, Karin Leander, Lars Lind, Anders Lindén, Nicola Orsini, Matteo Pirro, Angela Silveira, Andries J. Smit, Elena Tremoli, Fabrizio Veglia, Rona J. Strawbridge, Bruna Gigante
Background We investigated the causality of IL-8 on carotid intima-media thickness (c-IMT), a measure of sub-clinical atherosclerosis. Methods The IMPROVE is a multicenter European study (n = 3,711). The association of plasma IL-8 with c-IMT (mm) was estimated by quantile regression. Genotyping was performed using the Illumina CardioMetabo and Immuno chips. Replication was attempted in three independent